Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries
Table 2
Changing patient profiles in the subcategory “other” over 6 RSV seasons*.
Indication, (%)
RSV Season
2006-2007
2007-2008
2008-2009
2009-2010
2010-2011
2011-2012
Down syndrome
2 (2.8)
47 (27.8)
62 (20.8)
81 (17.5)
107 (20.9)
150 (27.9)
Cystic fibrosis
13 (18.1)
19 (11.2)
28 (9.4)
55 (11.9)
54 (10.6)
52 (9.7)
Congenital airway anomaly
16 (22.2)
46 (27.2)
50 (16.8)
66 (14.3)
91 (17.8)
75 (13.9)
Miscellaneous
41 (56.9)
57 (33.7)
158 (53)
260 (56.3)
259 (50.7)
261 (48.5)
Pulmonary disorders
13 (18.1)
12 (7.1)
65 (21.8)
90 (19.5)
89 (17.4)
73 (13.6)
Neuromuscular impairment
12 (16.7)
11 (6.5)
15 (5.0)
40 (8.7)
40 (7.8)
35 (6.5)
Immunocompromised
1 (1.4)
3 (1.8)
4 (1.3)
9 (1.9)
9 (1.8)
24 (4.5)
Cardiac disease ≥ 2 yr
0 (0.0)
7 (4.1)
7 (2.3)
7 (1.5)
10 (2.0)
11 (2.0)
Multisystem anomalies
5 (6.9)
6 (3.6)
32 (10.7)
15 (3.2)
30 (5.9)
41 (7.6)
Various medical disorders
10 (13.9)
18 (10.7)
35 (11.7)
99 (21.4)
81 (15.9)
77 (14.3)
The 2005-2006 season was excluded as this information was not collected sequentially in all the subcategories for that year.
